EyePoint posts updated investor presentation with LUGANO Phase 3 data; specifics not disclosed in excerpt

EyePoint, Inc.

EyePoint posted an updated investor presentation on September 10, 2026, on its website.
Presentation titled 'LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses'.
No specific efficacy, safety, or financial figures are included in the provided excerpt.
DURAVYU is being studied for wet age-related macular degeneration in the LUGANO Phase 3 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.